Antibody-Targeted Nanoparticles for Cancer Treatment

Abstract

Nanoparticles (NPs) are diverse and versatile with physical properties that can be employed for use in cancer medicine. Targeting NPs using antibodies and antibody fragments could overcome some of the limitations seen with current targeted therapies. This review will discuss the role of antibody-targeted NPs in the treatment of cancer: as delivery vehicles, targeted theranostic agents and in the evolving field of cancer hyperthermia.

Keywords::

• antibodies
• cancer treatment
• clinical translation
• hyperthermia
• nanoparticles
• targeting
• theranostics

Financial & competing interests disclosure

The authors are grateful for the support received from the Seventh Framework Programme (FP7) for DARPin targeted magnetic hyperthermic therapy for glioblastoma (Dartrix EC grant: 278580), the Department of Health and Cancer Research UK Experimental Cancer Medicine Centre (ECMC) and NIHR University College London Hospitals Biomedical Research Centre. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

The authors are grateful for the support received from the Seventh Framework Programme (FP7) for DARPin targeted magnetic hyperthermic therapy for glioblastoma (Dartrix EC grant: 278580), the Department of Health and Cancer Research UK Experimental Cancer Medicine Centre (ECMC) and NIHR University College London Hospitals Biomedical Research Centre. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.